Cue Biopharma, Inc.
CUE
$0.7767
$0.00831.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 69.16% | 149.53% | 363.98% | 1,525.00% | 340.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.16% | 149.53% | 363.98% | 1,525.00% | 340.96% |
| Cost of Revenue | -10.61% | 12.50% | 18.31% | 25.16% | 20.42% |
| Gross Profit | 22.44% | 3.25% | -0.06% | -6.20% | -8.70% |
| SG&A Expenses | -13.98% | -32.49% | -24.76% | -18.86% | -23.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.49% | -3.25% | 3.37% | 9.84% | 4.99% |
| Operating Income | 20.00% | 14.22% | 8.84% | 2.59% | 2.82% |
| Income Before Tax | 19.83% | 14.03% | 9.42% | 3.65% | 4.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.83% | 14.03% | 9.42% | 3.65% | 4.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.83% | 14.03% | 9.42% | 3.65% | 4.30% |
| EBIT | 20.00% | 14.22% | 8.84% | 2.59% | 2.82% |
| EBITDA | 19.91% | 13.95% | 8.43% | 2.02% | 2.18% |
| EPS Basic | 32.50% | 24.36% | 23.28% | 21.00% | 25.63% |
| Normalized Basic EPS | 32.13% | 24.52% | 23.56% | 21.70% | 26.24% |
| EPS Diluted | 32.50% | 24.36% | 23.28% | 21.00% | 25.63% |
| Normalized Diluted EPS | 32.13% | 24.52% | 23.56% | 21.70% | 26.24% |
| Average Basic Shares Outstanding | 23.01% | 13.19% | 17.79% | 21.51% | 28.37% |
| Average Diluted Shares Outstanding | 23.01% | 13.19% | 17.79% | 21.51% | 28.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |